Printer Friendly

Obagi Medical Products and Syneron to Study Effect of Obagi's Skin Care System as an Adjunct to Aesthetic Procedures.

LONG BEACH, Calif. -- Obagi Medical Products, Inc. (Nasdaq:OMPI), a leader in topical aesthetic and therapeutic skin health systems, today announced it has partnered with Syneron, Inc. (Nasdaq:ELOS) to initiate a multi-center, physician use study to assess the potential benefits of adjunctive use of Obagi's Nu-Derm Condition and Enhance[TM] skin care system with light-based aesthetic procedures. The clinical study will commence patient enrollment immediately.

This trial will evaluate the outcome of patients undergoing aesthetic facial procedures using the elys[R] combined-energy medical aesthetic devices developed by Syneron in conjunction with Obagi's newly developed, proprietary, prescription-strength Nu-Derm Condition and Enhance[TM] skin care systems. The experience trial will be conducted by physicians experienced with elys[R] devices, and is targeted for completion during 2007.

The global skin care market is estimated to exceed $36 billion, 62% of which is comprised of facial skin care products, according to an independent 2005 study by Kline & Co. Additionally, the independent research firm Kalorama Information estimates that more than 70 million people will receive cosmetic facial procedures between 2005 and 2010.

"A key development objective for Obagi includes developing skin care systems that enhance the effects of commonly performed cosmetic procedures," said Steve Carlson, President and CEO of Obagi Medical Products. "We already have clinical results that show our products enhance the health and aesthetic appearance of skin. We believe this study will show that the use of our Nu-Derm Condition and Enhance Systems will improve overall patient outcomes when used pre- and post-procedure in conjunction with laser cosmetic treatments."

Doron Gerstel, President of Syneron, Inc., added, "This study will help illustrate the synergy that can come from two proven approaches to facial rejuvenation, which we believe when combined will result in a very differentiated and effective solution that physicians will want to make available to their patients."

About Obagi Medical Products, Inc. (

Obagi Medical Products is a specialty pharmaceutical company focused on the aesthetic and therapeutic skin health markets. The company develops and commercializes prescription-based, topical skin health systems that enable physicians to treat a range of skin conditions, including pre-mature aging, photodamage, hyperpigmentation (irregular or patchy discoloration of the skin), acne and soft tissue deficits, such as fine lines and wrinkles. Obagi markets and sells physician-dispensed skin care systems directly to plastic surgeons, dermatologists and other physicians who are focused on aesthetic and therapeutic skin care. Obagi products are dispensed throughout the United States and in more than 35 other countries.

About Syneron (

Syneron Medical Ltd. manufactures and distributes medical aesthetic devices that are powered by the proprietary, patented elos combined-energy technology of Bi-Polar Radio Frequency and Light that allow physicians to provide advanced, highly effective, safe and cost-effective solutions for a broad range of medical-aesthetic applications, including hair removal, wrinkle reduction, rejuvenating the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. Syneron Medical Ltd. is located in Israel and has offices and distributors throughout the world, including Canada, Germany and Hong Kong.

Forward-Looking Statements

There are forward-looking statements contained herein, which can be identified by the use of forward-looking terminology such as the words "believes," "expects," "may," "will," "should", "potential," "anticipates," "plans" or "intends" and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from the future results, events or developments indicated in such forward-looking statements. Such factors include, but are not limited to the intense competition our products face and will face in the future, the level of market acceptance of our products, the possibility that our products could be rendered obsolete by technological or medical advances and the possibility that our products may cause undesirable side effects. A more detailed discussion of these and other factors that could affect results is contained in our filings with the U.S. Securities and Exchange Commission, including our Registration Statement on Form S-1. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. No assurance can be given that the future results covered by the forward-looking statements will be achieved. All information in this press release is as of the date of this press release and Obagi Medical Products does not intend to update this information.
COPYRIGHT 2007 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Feb 5, 2007
Previous Article:Research and Markets: Gain An Insight In To Wells Fargo & Company.
Next Article:GPS Security Leader, Inilex, Introduces Kepler Security System.

Related Articles

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters